Biosimilar Pegfilgrastim: Improving Access and Optimising Practice to Supportive Care that Enables Cure Paul CornesPere GasconMatti Aapro Current Opinion Open access 30 March 2020 Pages: 255 - 263
Ongoing Developments and Clinical Progress in Drug-Loaded Red Blood Cell Technologies Luigia RossiFrancesca PierigèMauro Magnani Leading Article Open access 20 March 2020 Pages: 265 - 272
In Vivo Delivery of Nucleic Acid-Encoded Monoclonal Antibodies Ami PatelMamadou A. BahDavid B. Weiner Leading Article Open access 10 March 2020 Pages: 273 - 293
Correction to: In Vivo Delivery of Nucleic Acid-Encoded Monoclonal Antibodies Ami PatelMamadou A. BahDavid B. Weiner Correction Open access 02 April 2020 Pages: 295 - 295
The Path Towards a Tailored Clinical Biosimilar Development Martin SchiestlGopinath RangannaJulie Maréchal-Jamil Review Article Open access 07 April 2020 Pages: 297 - 306
Haematopoietic Stem Cell Transplantation for Multiple Sclerosis: Current Status Alice MariottiniEleonora De MatteisPaolo A. Muraro Review Article 12 March 2020 Pages: 307 - 325
Cell-Free Protein Synthesis: A Promising Option for Future Drug Development Srujan Kumar DondapatiMarlitt StechStefan Kubick Review Article Open access 20 March 2020 Pages: 327 - 348
The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma Daniel R. AlmquistDaniel H. AhnTanios S. Bekaii-Saab Review Article 03 April 2020 Pages: 349 - 362
Demonstrating Analytical Similarity of Trastuzumab Biosimilar HLX02 to Herceptin® with a Panel of Sensitive and Orthogonal Methods Including a Novel FcγRIIIa Affinity Chromatography Technology Liqi XieErhui ZhangScott Liu Original Research Article Open access 18 February 2020 Pages: 363 - 379
Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial Jinmei SuMengtao LiXiaofeng Zeng Original Research Article Open access 20 February 2020 Pages: 381 - 393
Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study Stephanie L. HoFang NiuRita L. Hui Original Research Article Open access 26 February 2020 Pages: 395 - 404
Correction to: Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study Stephanie L. HoFang NiuRita L. Hui Correction Open access 06 April 2020 Pages: 405 - 405